Pharmabiz7h
Merck to present new data from Gardasil 9 studies reinforcing the importance of gender-neutral HPV vaccination in adults up to age 45 at IPVC 2024
Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Medpage Today on MSN1d
Real-World Data on the RSV Vaccine for Older Adults
Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
FiercePharma12d
Gardasil's China troubles haunt Merck in Q3, with execs warning of more obstacles ahead
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...
Merck: An Undervalued Dividend Machine
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.
NBC DFW13d
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. But Merck's vaccine that ...